Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: A randomized, controlled, crossover trial of 12 healthy male subjects

Journal of Clinical Psychiatry

Volumn 66, Issue 8, 2005, Pages 989-996

  Cohrs, Stefan ^a,b   Meier, Andreas ^a   Neumann, Anna Catharina ^a   Jordan, Wolfgang ^a   Rüther, Eckart ^a   Rodenbeck, Andrea ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Department of Psychiatry and Psychotherapy ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; PLACEBO; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SLEEP PARAMETERS; SLEEP PATTERN; SLEEP STAGE; SLEEP TIME; SLOW WAVE SLEEP;

EID: 23944483144     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0805     Document Type: Article

References (66)

1. Toben M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-1088
2. Calabrese JR, Macfadden W, McCoy R, et al. Double-blind, placebo-controlled study of quetiapine in bipolar depression. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
3. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004;65:217-221
4. Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004;65:975-981
5. Benca RM, Obermeyer WH, Thisted RA, et al. Sleep and psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 1992;49:651-668
6. Riemann D, Berger M, Voderholzer U. Sleep and depression: results from psychobiological studies: an overview. Biol Psychol 2001;57:67-103
7. Caldwell DF, Domino EF. Electroencephalographic and eye movement patterns during sleep in chronic schizophrenic patients. Electroencephalogr Clin Neurophysiol 1967;22:414-420
8. Zarcone VP, Benson KL, Berger PA. Abnormal rapid eye movement latencies in schizophrenia. Arch Gen Psychiatry 1987;44:45-48
9. Kempenaers C, Kerkhofs M, Linkowski P, et al. Sleep EEG variables in young schizophrenic and depressive patients. Biol Psychiatry 1988;24:833-838
10. Lauer CJ, Schreiber W, Pollmacher T, et al. Sleep in schizophrenia: a polysomnographic study on drug-naive patients. Neuropsychopharmacology 1997;16:51-60
11. Keshavan MS, Reynolds CF III, Miewald MJ, et al. Delta sleep deficits in schizophrenia: evidence from automated analyses of sleep data. Arch Gen Psychiatry 1998;55:443-448
12. Ganguli R, Reynolds CF III, Kupfer DJ. Electroencephalographic sleep in young, never-medicated schizophrenics: a comparison with delusional and nondelusional depressives and with healthy controls. Arch Gen Psychiatry 1987;44:36-44
13. Tandon R, DeQuardo JR, Taylor SF, et al. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome [Erratum in Schizophr Res 2001;51:185]. Schizophr Res 2000;45:191-201
14. Keshaven MS, Reynolds CF III, Miewald J, et al. Slow-wave sleep deficits and outcome in schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 1995;91:289-292
15. Tandon R, Shipley JE, Taylor S, et al. Electroencephalographic sleep abnormalities in schizophrenia: relationship to positive/negative symptoms and prior neuroleptic treatment. Arch Gen Psychiatry 1992;49:185-194
16. Touyz SW, Beumont PJ, Saayman GS, et al. A psychophysiological investigation of the short-term effects of clozapine upon sleep parameters of normal young adults. Biol Psychiatry 1977;12:801-822
17. Hinze Selch D, Mullington J, Orth A, et al. Effects of clozapine on sleep: a longitudinal study. Biol Psychiatry 1997;42:260-266
18. Wetter TC, Lauer CJ, Gillich G, et al. The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs. J Psychiatr Res 1996;30:411-419
19. Lee JH, Woo JI, Meltzer HY. Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia. Psychiatry Res 2001;103:157-166
20. Sharpley AL, Vassallo CM, Cowen PJ. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT(2C) receptors in vivo. Biol Psychiatry 2000;47:468-470
21. Salin-Pascual RJ, Herrera-Estrella M, Galicia-Polo L, et al. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 1999;46:141-143
22. Cohrs S, Rodenbeck A, Guan Z, et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl) 2004;174:421-429
23. Sharpley AL, Bhagwagar Z, Hafizi S, et al. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. J Clin Psychiatry 2003;64:192-196
24. Sharpley AL, Cowen PJ. Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 1995;37:85-98
25. Rijnbeek B, de Visser SJ, Franson KL, et al. REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteers. J Psychopharmacol 2003;17:196-203
26. Winokur A, Gary KA, Rodner S, et al. Depression, sleep physiology, and antidepressant drugs. Depress Anxiety 2001;14:19-28
27. Gursky JT, Krahn LE. The effects of antidepressants on sleep: a review. Harv Rev Psychiatry 2000;8:298-306
28. Harvey PD. Ziprasidone and cognition: the evolving story. J Clin Psychiatry 2003;64(suppl 19):33-39
29. Harvey PD, Meltzer H, Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 2004;66:101-113
30. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001;155:128-134
31. Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol 2000;49(suppl 1):5s-13s
32. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275:101-113
33. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003;64(suppl 19):6-12
34. Tatsumi M, Jansen K, Blakely RD, et al. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999;368:277-283
35. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 2002;36:839-851
36. Schmidt AW, Lebel LA, Howard HR Jr, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197-201
37. Cluydts R, De Roeck J, Cosyns P, et al. Antagonizing the effects of experimentally induced sleep disturbance in healthy volunteers by lormetazepam and zolpidem. J Clin Psychopharmacol 1995;15:132-137
38. Kane JM. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. J Clin Psychiatry 2003;64(suppl 19):19-25
39. Görtelmeyer R. Schlaffragebogen SF-A and SF-B [in German]. In: Collegium Internationale Psychiatriae Scalarum (CIPS), ed. Internationale Skalen für Psychiatrie. Weinheim, Germany: Beltz; 1981
40. Ott H, Oswald I, Fichte K, et al. Visuelle Analogskalen zur Erfassung von Schlalfqualität [in German]. In: Collegium Internationale Psychiatriae Scalarum (CIPS), ed. Internationale Skalen für Psychiatrie. Weinheim, Germany: Beltz; 1986
41. Penzel T, Hajak G, Hoffmann RM, et al. Empfehlungen zur Durchführung und Auswertung polygraphischer Ableitungen im diagnostischen Schlaflabor [in German]. EEG-EMG-Z ELEK ELEKT 1993;24:65-70
42. Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Washington, DC: United States Government Printing Office; 1968. Public Health Service publication 204
43. Coleman RM. Periodic movements in sleep (nocturnal myoclonus) and restless legs syndrome. In: Guilleminault C, ed. Sleeping and Waking Disorders: Indications and Techniques. Menlo Park, Calif: Addison-Wesley; 1982:265-295
44. Cross EM, Chaffin WW. Use of the binomial theorem in interpreting results of multiple tests of significance. Educ Psychol Meas 1982;42:25-34
45. Rüther E, Davis L, Papousek M, et al. Pharmakologische Beeinflussung zentraler serotonerger Mechanismen am Menschen und Auswirkungen auf den Schlaf [in German]. Arzneimittelforschung 1976;26:1071-1073
46. Sharpley AL, Vassallo CM, Pooley EC, et al. Allelic variation in the 5-HT2C receptor (HT2RC) and the increase in slow wave sleep produced by olanzapine [letter]. Psychopharmacology (Berl) 2001;153:271-272
47. Yamashita H, Morinobu S, Yamawaki S, et al. Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol. Psychiatry Res 2002;109:137-142
48. van Bemmel AL. The link between sleep and depression: the effects of antidepressants on EEG sleep. J Psychosom Res 1997;42:555-564
49. Asian S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 2002;25:677-679
50. Vogel GW, Thurmond A, Gibbons P, et al. REM sleep reduction effects on depression syndromes. Arch Gen Psychiatry 1975;32:765-777
51. Hobson JA, McCarley RW, Wyzinski PW. Sleep cycle oscillation: reciprocal discharge of two brainstem neuronal groups. Science 1975;189:55-58
52. Hobson JA, Pace-Schott EF, Stickgold R. Dreaming and the brain: toward a cognitive neuroscience of conscious states [Erratum in Behav Brain Sci 2001;24:575]. Behav Brain Sci 2000;23:793-842
53. Kupfer DJ, Foster FG, Reich L, et al. EEG sleep changes as predictors in depression. Am J Psychiatry 1976;133:622-626
54. Riemann D, Velthaus S, Laubenthal S, et al. REM-suppressing effects of amitriptyline and amitriptyline-N-oxide after acute medication in healthy volunteers: results of two uncontrolled pilot trials. Pharmacopsychiatry 1990;23:253-258
55. Kupfer DJ, Coble P, Kane J, et al. Imipramine and EEG sleep in children with depressive symptoms. Psychopharmacology (Berl) 1979;60:117-123
56. Yamadera H, Nakamura S, Suzuki H, et al. Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects. Psychiatry Clin Neurosci 1998;52:439-443
57. Armitage R, Emslie G, Rintelmann J. The effect of fluoxetine on sleep EEG in childhood depression: a preliminary report. Neuropsychopharmacology 1997;17:241-245
58. Reynolds CF III, Buysse DJ, Brunner DP, et al. Maintenance nortriptyline effects on electroencephalographic sleep in elderly patients with recurrent major depression: double-blind, placebo- and plasma-level-controlled evaluation. Biol Psychiatry 1997;42:560-567
59. Trivedi MH, Rush AJ, Armitage R, et al. Effects of fluoxetine on the polysomnogram in outpatients with major depression. Neuropsychopharmacology 1999;20:447-459
60. Feige B, Voderholzer U, Riemann D, et al. Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. Neuropsychopharmacology 2002;26:246-258
61. Okuma T, Hata N, Fujii S. Differential effects of chlorpromazine, imipramine, nitrazepam and amobarbital on REM sleep and REM density in man. Folia Psychiatr Neurol Jpn 1975;29:25-37
62. Gillin JC, Jernajczyk W, Valladares-Neto DC, et al. Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers. Psychopharmacology (Berl) 1994;116:433-436
63. Gillin JC, Sohn JW, Stahl SM, et al. Ipsapirone, a 5-HT1A agonist, suppresses REM sleep equally in unmedicated depressed patients and normal controls. Neuropsychopharmacology 1996;15:109-115
64. De Gennaro L, Ferrara M, Bertini M. The relationship between frequency of rapid eye movements in REM sleep and SWS rebound. J Sleep Res 2000;9:155-159
65. Paiva T, Arriaga F, Wauquier A, et al. Effects of ritanserin on sleep disturbances of dysthymic patients. Psychopharmacology (Berl) 1988;96:395-399
66. Sharpley AL, Elliott JM, Attenburrow MJ, et al. Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. Neuropharmacology 1994;33:467-471